Cubist won Food and Drug Administration approval in 2003 to market Cubicin, after several years of research and development. The drug is mainly used to fight skin infections caused by certain bacteria.
(PHOTOS BY Jonathan Wiggs/Globe Staff)
For Cubist, a tough sell
Despite robust US sales of its antibiotic Cubicin, the Lexington biotech finds global success is difficult to achieve
Cubist won Food and Drug Administration approval in 2003 to market Cubicin, after several years of research and development. The drug is mainly used to fight skin infections caused by certain bacteria.
(PHOTOS BY Jonathan Wiggs/Globe Staff)
Since Cubist Pharmaceuticals Inc. launched its first drug five years ago - an antibiotic called Cubicin - sales have skyrocketed. (Full article: 848 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
